Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3996MR)

This product GTTS-WQ3996MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3996MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8557MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ1354MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ944MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ14420MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ2587MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ10113MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ848MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ1696MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW